Speech-Language Pathologists in Carnegie, PA Accepting Medicare

6 Speech-Language Pathologists found. Showing 1 - 6

Gretchen Michelle Wortman Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1100 Washington Ave Ste 317, Carnegie, PA 15106 Phone: 412-439-7572

Christine Lepore Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 1100 Washington Ave Ste 317, Carnegie, PA 15106 Phone: 412-489-5527

Megan C Joseph, MSLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 112 3rd Ave, Carnegie, PA 15106 Phone: 412-429-7760

Rsi Pennsylvania Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 112 3rd Ave, Carnegie, PA 15106 Phone: 412-429-7760    Fax: 412-429-7762

Ican Talk Clinic Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1100 Washington Ave Ste 317, Carnegie, PA 15106 Phone: 412-489-5527    Fax: 412-489-5726

Cassandra Marie Bortot, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1100 Washington Ave Ste 317, Carnegie, PA 15106 Phone: 412-489-5527    Fax: 412-489-5726

News Archive

New study finds how the body adapts to occasional short-term overeating

Overeating has been found to impair blood sugar (glucose) control and insulin levels. A new study suggests that the duration of a bout of overeating can affect how the body adapts glucose and insulin processing when calorie intake increases.

Re-engineered human T cells effectively target and kill cancerous B cells

Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC).

Bio-Path commences dosing in Liposomal Grb-2 Phase I cancer study

Bio-Path Holdings, Inc.,, a biotechnology company with drug development operations in Houston, Texas, announced today that the first patient has been dosed in a Phase I study of its cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), in patients with Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) or Myelodysplastic Syndrome (MDS).

Scientists create new strain of polio to protect vaccine factory workers

"Scientists have created new strains of polio intended to protect workers in factories that make polio vaccine," the New York Times reports.

NABsys to utilize $7M Series B funding for accelerating DNA sequencing platform development

NABsys Inc., the pioneer in electronic, solid-state DNA sequencing, today announced that it has received a $7 million investment as part of a Series B equity round led by Stata Venture Partners. The funding will be used to accelerate the development and commercialization of the company's proprietary DNA sequencing platform, which leverages semiconductor technology to achieve the scope and scale required for full integration of genomics into medicine.

Read more Medical News

› Verified 2 days ago